Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

SAN DIEGO--(BUSINESS WIRE)--Nov 18, 2026-- Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced positive preliminary clinical data from the Phase 1 portion of the Phase 1/2 AVENTINE-1 study evaluating AVZO-1418 in patients with locally...

Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

SAN DIEGO, November 18, 2026--Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific ADC This is a paid press release. Contact the press release distributor directly with any inquiries. Avenzo Therapeutics...

EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies

Abstract Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity,...

Case report and literature review: efficacy of afatinib in a rare EGFR p.G719A/p.H773L compound-mutant NSCLC with over 54 months of progression-free survival

Compound EGFR mutations involving an exon 18 sensitizing variant and an exon 20 non-insertion point mutations pose a therapeutic dilemma: the former predicts 1 Background Epidermal growth factor receptor (EGFR) mutations are among the most actionable oncogenic drivers in non-small...

FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results

FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results Summit Therapeutics announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its biologics license application for ivonescimab plus platinum-containing chemotherapy in previously...

Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK-Mutated Non–Small-Cell Lung Cancer

Introduction The phase 3 ATTLAS study demonstrated that atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP) improved progression-free survival compared with pemetrexed-carboplatin/cisp 1 Introduction Patients with advanced non–small-cell lung cancer (NSCLC) harboring EGFR mutations or ALK rearrangements generally receive substantial benefit...

A Necroptosis-Related Seven-Gene Risk Score Stratifies Prognosis and Predicts Immunotherapy Response and EGFR-TKI Sensitivity in Lung Adenocarcinoma

Background Necroptosis is a regulated form of inflammatory cell death with context-dependent roles in tumor progression and immune regulation. However, the prognostic value and therapeutic implicati 1 Introduction Lung cancer remains the leading cause of cancer-related death worldwide, accounting for...

Federica Pecci: Predictors of Early Progression on First-Line Osimertinib in EGFR-Mutant NSCLC

Federica Pecci: Predictors of Early Progression on First-Line Osimertinib in EGFR-Mutant NSCLC “Glad to share our manuscript just published in JTO investigating the clinicogenomic determinants of earlier progression with osimertinib monotherapy in EGFR-mutant NSCLC. To study early osimertinib progression further,...

Acetyl tributyl citrate promotes osteosarcoma progression via EGFR/AKT signaling: an integrated network toxicology and experimental study

IntroductionAcetyl tributyl citrate (ATBC), a widely used plasticizer, has raised health concerns, yet its role in osteosarcoma (OS) remains unclear. This st 1 Introduction Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children and adolescents, typically arising...